secwatch.observer — SEC 8-K summary
======================================

Issuer:     Werewolf Therapeutics, Inc. (HOWL)
CIK:        0001785530
Form:       8-K
Filed at:   2026-07-31T11:06:21+00:00
Accession:  0001785530-26-000018
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Werewolf Q2 net income $3.7M on $21M asset sale; cash runway into Q2 2027
-------------------------------------------------------------------------

- Net income of $3.7M vs net loss of $18.0M in Q2 2025; collaboration revenue of $21.0M from JZP898 sale to Jazz.
- Cash and equivalents $22.0M as of June 30, 2026, down from $46.5M at March 31, 2026; expects to fund operations into Q2 2027.
- R&D expenses decreased to $6.2M from $13.1M; G&A increased to $7.7M from $4.4M.
- Exploring strategic alternatives with Piper Sandler; expects data updates on WTX-124 and WTX-330 in H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785530/000178553026000018/0001785530-26-000018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785530/000178553026000018/howl-20260731.htm
  HTML page:      https://secwatch.observer/filing/0001785530-26-000018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer